Experienced in Malignant Mixed Mullerian Tumor

Dr. Karthik Koduru

Hematology Oncology | Hospital Medicine | Hematology
Dallas, TX 
Experienced in Malignant Mixed Mullerian Tumor
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Karthik Koduru is a Hematologist Oncology specialist and a Hospital Medicine provider in Dallas, Texas. Dr. Koduru is rated as an Experienced provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Small Cell Lung Cancer (SCLC), Colonoscopy, and Endoscopy.

His clinical research consists of participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hospital Medicine
Hematology
Licenses
Internal Medicine in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 1 Less Insurance Carrier -

Locations

Dallas, TX 75265

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
View 2 Less Clinical Trials
Similar Doctors
Distinguished in Malignant Mixed Mullerian Tumor
Dr. Deette R. Vasques
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Malignant Mixed Mullerian Tumor
Dr. Deette R. Vasques
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Oncology-Hematology Consultants PA

6100 Harris Pkwy, Suite 235, 
Fort Worth, TX 
 (36.7 miles away)
817-759-7000
Languages Spoken:
English, Hindi, Mandarin, Spanish, Taiwanese
See accepted insurances
Accepting New Patients
Offers Telehealth

Deette Vasques is a Gynecologic Oncologist and an Oncologist in Fort Worth, Texas. Dr. Vasques is rated as a Distinguished provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. Her top areas of expertise are Malignant Mixed Mullerian Tumor, Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, Vulvectomy, and Ureteroscopy. Dr. Vasques is currently accepting new patients.

Distinguished in Malignant Mixed Mullerian Tumor
Dr. Mark J. Messing
Oncology | Obstetrics and Gynecology
Distinguished in Malignant Mixed Mullerian Tumor
Dr. Mark J. Messing
Oncology | Obstetrics and Gynecology

Texas Oncology, P.A.

1615 Hospital Parkway, Suite 300, 
Bedford, TX 
 (18.9 miles away)
817-678-8031
Experience:
41+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mark Messing is an Oncologist and an Obstetrics and Gynecologist in Bedford, Texas. Dr. Messing has been practicing medicine for over 41 years and is rated as a Distinguished provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. His top areas of expertise are Desmoplastic Small Round Cell Tumor, Endometrial Cancer, Malignant Mixed Mullerian Tumor, Hernia Surgery, and Oophorectomy.

Distinguished in Malignant Mixed Mullerian Tumor
Dr. Claude A. Stringer
Gynecologic Oncology | Oncology
Distinguished in Malignant Mixed Mullerian Tumor
Dr. Claude A. Stringer
Gynecologic Oncology | Oncology
3410 Worth St, 
Dallas, TX 
 (1.7 miles away)
214-370-1301
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Claude Stringer is a Gynecologic Oncologist and an Oncologist in Dallas, Texas. Dr. Stringer is rated as a Distinguished provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. His top areas of expertise are Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, Testicular Yolk Sac Tumor, Malignant Mixed Mullerian Tumor, and Oophorectomy. Dr. Stringer is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Koduru's expertise for a condition
ConditionClose
    View All 17 Advanced Conditions
    View All 93 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile